New York’s Cannabis Equity Licensing Model Is in Constitutional Free Fall

NEW YORK — There’s a legal reckoning unfolding inside federal courtrooms that could unwind years of equity licensing delays work in New York’s cannabis industry — and the implications stretch far beyond the Hudson River.

Last Wednesday, a federal judge in the Southern District of New York rejected the state’s bid to dismiss a constitutional challenge to its cannabis licensing program. The ruling — coming less than eight months after the Second Circuit Court of Appeals struck down New York’s signature equity preference for applicants with in-state marijuana convictions — confirms that the courts aren’t done with Albany yet.

For an industry that was supposed to be the national model for restorative justice, it’s been a rough few months.

How We Got Here

New York’s adult-use licensing framework, built into the Marijuana Regulation and Taxation Act of 2021, was architected explicitly around social equity. Its centerpiece: an “Extra Priority” track that bumped applicants with New York-specific cannabis convictions — and their family members — to the front of the licensing queue. The theory was straightforward. The people most harmed by prohibition enforcement should have a head start in the legal market.

It was a politically popular idea. It was also, according to a split panel of the Second Circuit, unconstitutional.

In Variscite NY Four, LLC v. New York State Cannabis Control Board, decided in August 2025, the appeals court held that the Extra Priority scheme violated the dormant Commerce Clause — the constitutional doctrine that bars states from discriminating against out-of-state economic interests in interstate commerce. The plaintiffs, a group of multi-state operators who met two of New York’s three equity criteria (community residency and income threshold), were excluded from Extra Priority solely because their principal’s marijuana conviction occurred in California rather than New York. The Second Circuit called that distinction a protectionist measure that couldn’t survive constitutional scrutiny.

It was a landmark ruling. It was also just round one.

The New Lawsuit

On March 25, U.S. District Judge [in the SDNY] declined to dismiss a follow-on constitutional challenge, letting another group of plaintiffs press their case that New York’s broader cannabis licensing structure remains infected by dormant Commerce Clause problems. The state’s cannabis regulators — the Office of Cannabis Management and the Cannabis Control Board — had argued the case should be thrown out. The judge disagreed.

The details of the surviving claims make clear this is not a clean fight. The dormant Commerce Clause question itself is now subject to a full-blown circuit split: the 1st and 2nd Circuits say the doctrine applies to state cannabis markets; the 9th Circuit, in a January 2026 ruling out of Washington State, said it does not. The Supreme Court hasn’t weighed in yet, but with three circuits and a $38 billion industry producing conflicting results, that won’t last.

For New York’s roughly 2,161 licensed adult-use operators — and the hundreds more waiting in the pipeline — the uncertainty is real and compounding.

What This Means for New York Operators

The immediate practical consequences of the Variscite ruling were already significant. The Extra Priority queue had been central to New York’s Conditional Adult-Use Retail Dispensary (CAURD) program, which fast-tracked licenses to justice-involved entrepreneurs. With that preference now struck, the OCM has had to reconfigure its licensing review process, and the equity-focused $6 million grant program announced by the CCB in March — designed to reach roughly 190 licensees — exists partly to compensate for the market access disruption.

But equity grants don’t solve a constitutional problem. If additional licensing preferences in New York’s framework fall to dormant Commerce Clause challenges, the state’s ability to engineer social equity outcomes through licensing will be severely constrained.

“The issue,” as one cannabis attorney put it in the Reuters coverage of the Variscite fallout, “is that states want to repair local harm done by local enforcement of laws that were locally enforced disproportionately — but the Constitution doesn’t easily allow you to draw that geographic circle.”

That’s not an abstraction for the small operators who structured their entire business cases around equity priority. Some borrowed against it. Some turned down other opportunities. Now they’re watching the courts redraw the rules mid-game.

The National Domino Effect

New York’s equity licensing architecture wasn’t unique. Similar state-conviction or residency preferences exist in New Jersey, Maryland, Connecticut, and Massachusetts — all states in this corridor that built equity provisions into their adult-use frameworks with New York as the template.

The 1st Circuit’s 2022 Northeast Patients Group ruling already put Maine’s residency requirements in the crosshairs. The Variscite ruling extended that logic south. If the Supreme Court ultimately sides with the 2nd Circuit’s interpretation — that the dormant Commerce Clause does apply to cannabis licensing, federal illegality notwithstanding — states from Maine to Maryland will need to audit their equity schemes for constitutional exposure.

New Jersey, which does not allow personal home cultivation specifically to protect its retail market, and which has its own robust social equity licensing tier, is watching the New York litigation closely. Maryland regulators, who built residency and disproportionately-impacted-area preferences into their adult-use rollout, are in a similar position. Connecticut’s social equity council structure, which controls a significant share of licenses, could face similar challenges.

The irony is sharp: the constitutional doctrine being weaponized against equity licensing was designed to prevent states from protecting local economic interests at the expense of interstate commerce. It’s now being used — successfully — to prevent states from protecting communities historically targeted by that same interstate market’s prohibition-era enforcement.

Albany’s Options Are Narrowing

New York’s response to Variscite has, so far, been administrative and financial rather than legislative. The OCM continues processing applications on a rolling basis, and the newly appointed acting executive director John Kagia has emphasized market stability and compliance. The CCB chair, Jessica Garcia, has framed continued licensing approvals as community investment.

That messaging is appropriate for the market. It doesn’t address the legal exposure.

What Albany hasn’t done yet — and may need to do — is redesign equity preferences around criteria that don’t explicitly draw a geographic boundary around New York convictions or residency. Federal courts have signaled they’ll accept equity-adjacent proxies that are facially neutral on state residency: income thresholds, proximity to disproportionately impacted communities, individual economic disadvantage. What they won’t accept is a New York-conviction-in-New-York litmus test.

The Supreme Court may ultimately resolve the circuit split and give states more flexibility. Or it may not. Operators and investors building around New York’s equity architecture right now are underwriting constitutional risk — and most of them know it.

The CCB meets Thursday. The NJ Cannabis Regulatory Commission meets Tuesday. There’s a lot of regulatory machinery still turning. But the legal foundation it’s built on is shaking, and nobody in the Northeast cannabis market should pretend otherwise.

Dana Reeves covers the Northeast cannabis market for CannabisInquirer.com. She is based in New York City.